CY1113121T1 - Υγρες συνθεσεις lh - Google Patents

Υγρες συνθεσεις lh

Info

Publication number
CY1113121T1
CY1113121T1 CY20121100836T CY121100836T CY1113121T1 CY 1113121 T1 CY1113121 T1 CY 1113121T1 CY 20121100836 T CY20121100836 T CY 20121100836T CY 121100836 T CY121100836 T CY 121100836T CY 1113121 T1 CY1113121 T1 CY 1113121T1
Authority
CY
Cyprus
Prior art keywords
liquid compositions
liquid
monodosed
pharmaceutical compositions
relates
Prior art date
Application number
CY20121100836T
Other languages
English (en)
Inventor
Rita Agostinetto
Fabrizio Samaritani
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1113121T1 publication Critical patent/CY1113121T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αναφέρεται σε υγρές φαρμακευτικές συνθέσεις ωχρινοποιητικής ορμόνης (LH) μονοδοσική χορήγηση ή για χορήγηση πολλαπλών δόσεων.
CY20121100836T 2007-11-01 2012-09-13 Υγρες συνθεσεις lh CY1113121T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28
EP08844750A EP2219607B1 (en) 2007-11-01 2008-10-29 Liquid LH formulations

Publications (1)

Publication Number Publication Date
CY1113121T1 true CY1113121T1 (el) 2016-04-13

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100836T CY1113121T1 (el) 2007-11-01 2012-09-13 Υγρες συνθεσεις lh

Country Status (26)

Country Link
US (1) US8664369B2 (el)
EP (1) EP2219607B1 (el)
JP (1) JP5551601B2 (el)
KR (1) KR101513181B1 (el)
CN (1) CN101842083B (el)
AU (1) AU2008320844B2 (el)
BR (1) BRPI0818324B8 (el)
CA (1) CA2700662C (el)
CY (1) CY1113121T1 (el)
DK (1) DK2219607T3 (el)
EA (1) EA019432B1 (el)
EC (1) ECSP10010224A (el)
ES (1) ES2393233T3 (el)
HK (1) HK1145443A1 (el)
HR (1) HRP20120660T1 (el)
IL (1) IL205105A (el)
MX (1) MX2010004639A (el)
MY (1) MY153976A (el)
NZ (1) NZ583991A (el)
PL (1) PL2219607T3 (el)
PT (1) PT2219607E (el)
RS (1) RS52566B (el)
SI (1) SI2219607T1 (el)
UA (1) UA101484C2 (el)
WO (1) WO2009056569A1 (el)
ZA (1) ZA201001907B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
EP2451437B1 (de) * 2009-07-06 2016-11-02 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
EP2533800B1 (en) * 2010-02-12 2016-07-20 Intas Pharmaceuticals Ltd. Liquid formulation of follicle stimulating hormone
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2015006997A (es) * 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
BR9510567A (pt) * 1995-03-21 1998-06-23 Applied Research Systems Formulaçoes líquidas de hcg
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
SI1599222T1 (sl) * 2003-01-08 2009-08-31 Novartis Vaccines & Diagnostic Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
KR101105486B1 (ko) * 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제

Also Published As

Publication number Publication date
EA019432B1 (ru) 2014-03-31
US20100261649A1 (en) 2010-10-14
JP2011502968A (ja) 2011-01-27
HRP20120660T1 (hr) 2012-09-30
EP2219607B1 (en) 2012-08-15
PT2219607E (pt) 2012-08-31
US8664369B2 (en) 2014-03-04
KR101513181B1 (ko) 2015-04-21
IL205105A0 (en) 2010-11-30
MX2010004639A (es) 2010-08-04
EA201070549A1 (ru) 2010-10-29
HK1145443A1 (en) 2011-04-21
BRPI0818324B8 (pt) 2021-05-25
AU2008320844A1 (en) 2009-05-07
SI2219607T1 (sl) 2012-09-28
KR20100088147A (ko) 2010-08-06
NZ583991A (en) 2012-02-24
CA2700662C (en) 2015-10-13
CA2700662A1 (en) 2009-05-07
PL2219607T3 (pl) 2012-12-31
EP2219607A1 (en) 2010-08-25
BRPI0818324B1 (pt) 2019-12-24
ECSP10010224A (es) 2010-07-30
RS52566B (en) 2013-04-30
BRPI0818324A2 (pt) 2017-05-16
AU2008320844B2 (en) 2013-08-29
CN101842083A (zh) 2010-09-22
UA101484C2 (en) 2013-04-10
ZA201001907B (en) 2011-05-25
DK2219607T3 (da) 2013-06-17
ES2393233T3 (es) 2012-12-19
JP5551601B2 (ja) 2014-07-16
IL205105A (en) 2015-04-30
MY153976A (en) 2015-04-30
CN101842083B (zh) 2012-11-14
WO2009056569A1 (en) 2009-05-07
WO2009056569A9 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
CY1113121T1 (el) Υγρες συνθεσεις lh
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA200802008A1 (ru) Фармацевтические композиции
BRPI1014956A2 (pt) agentes antinflamatórios.
EA201490644A1 (ru) Терапевтические пептиды
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UA107791C2 (en) Pesticidal compositions
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
DE602008002205D1 (de) Neuartige verbindungen
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP11011054A (es) Péptidos antivirales terapéuticos
DK2355867T3 (da) Anordning til medikamentafgivelse
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
BRPI1016190A2 (pt) compostos farmacêuticos.
BRPI0925077A2 (pt) Conjunto dispensador.
UA108636C2 (xx) Пептид
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.